Clinical trials: Gastrointestinal Reflux
GERD, Gastroesophageal Reflux Disease
RELIEF Europe Study
The purpose of this study is to evaluate the LINX device in patients who have previously undergone laparoscopic sleeve gastrectomy (LSG) for obesity and have chronic gastroesophageal reflux disease (GERD).
- Conditions
- GERD, Gastroesophageal Reflux Disease, Obesity, LSG
- Trial name
- NCT02762487
- Testing
- The LINX® Reflux Management System
- Where
- 4 sites in Germany, Italy
- Volunteers
- 7 people
- Sponsor
- Torax Medical Incorporated
GERD
Gastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs) Allocate Their GERD Patients to the Three GERD Patient Segments
Document how Swiss GPs allocate their GERD patients to the three GERD patient segments (according to King et al.) and how treated GERD patients are affected by their GERD treatment
- Trial name
- NCT00688675
- Where
- Switzerland
- Volunteers
- 2,912 people
- Sponsor
- AstraZeneca
GERD, EPS
Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS
Comparison of Neobianacid® clinical efficacy to omeprazole in relief of heartburn or epigastric pain
- Trial name
- NCT03238534
- Testing
- Neobianacid®, Omeprazole 20mg
- Where
- 12 sites in Italy
- Volunteers
- 275 people
- Sponsor
- Aboca Spa Societa' Agricola
Gastroesophageal Reflux
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
This PMS study had the objective to evaluate under ordinary medical care conditions the efficacy and tolerability of esomeprazole in patients who where treated by general practitioners and internists.
- Trial name
- NCT00567021
- Volunteers
- 67,130 people
- Sponsor
- AstraZeneca
GERD
An Epidemiological Study to Describe Symptom Control and Impact of Gastroesophageal Reflux Disease
The purpose of this study is to examine patient's perspective of symptom control and impact of gastroesophageal reflux disease (GERD) on daily life.
- Trial name
- NCT01134367
- Where
- 7 sites in Serbia
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease (GERD)
Medigus Ultrasonic Surgical Endostapler (MUSE) Registry
This registry is intended as an observational, post-marketing surveillance tool. The registry allows collection of baseline demographics and user experience of the commercially available MUSE system.
- Trial name
- NCT02366169
- Testing
- Medigus Ultrasonic Surgical Endostapler (MUSE) Procedure
- Where
- 16 sites in United States, Germany and 1 more
- Volunteers
- 200 people
- Sponsor
- Medigus Ltd
Gastro Esophageal Reflux
Effect of a Combination of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate on Subjects With GastroEsophageal Reflux Disease
The aim of this study is to investigate whether a 3-week treatment with an oral melt in mouth medical device, made up with hyaluronic acid, chondroitin sulphate and magnesium trisilicate, can lead to a reduction of…
- Trial name
- NCT03883074
- Testing
- hyaluronic acid with chondroitin + sulphate + magnesium trisilicate
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- SOFAR S.p.A.
GERD
Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients
The purpose of this study is to assess the difference between esomeprazole and placebo in the treatment of signs and symptoms as observed by 8-hour video and cardiorespiratory monitoring in neonatal patients.
- Trial name
- NCT00427635
- Testing
- Esomeprazole
- Where
- 3 sites in Australia, Germany and 1 more
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Hiatal Hernia With Gastroesophageal Reflux Disease, Gastroesophageal Reflux
Complications, Outcomes and Revisions Following Hiatal Hernia Repair With MIROMESH
Investigator will identify a consecutive cohort of patients who have undergone a hiatal hernia repair and are at least 6 months post index procedure.
- Conditions
- Hiatal Hernia With Gastroesophageal Reflux Disease, Gastroesophageal Reflux, GERD
- Trial name
- NCT03735862
- Testing
- Hepatic derived surgical matrix
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Miromatrix Medical Inc.
Gastrointestinal Health
Viome Nutritional Programs to Improve Clinical Outcomes for Gastrointestinal Conditions
US residents who have gastrointestinal issues sign the informed consent form and are screened and enrolled for this study. Participants who are enrolled complete a survey upon enrollment and are randomized into one of three arms.
- Trial name
- NCT05465629
- Testing
- VIOME Precision Nutrition Program, VIOME-designed condition-based supplements
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Viome
Gastroesophageal Reflux Disease (GERD)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)
This study includes patients with sleep disturbances associated with gastroesophageal reflux disease (GERD) and has 3 treatment arms.
- Trial name
- NCT00628342
- Testing
- Esomeprazole
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers
The purpose of the study is to evaluate and compare the pharmacokinetics (blood levels) of 2 different formulations, assess the effect of food on the pharmacokinetics and assess safety of rabeprazole sodium in healthy volunteers.
- Trial name
- NCT01101646
- Testing
- rabeprazole sodium
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Reflux Esophagitis, Gastroesophageal Reflux
A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis
A phase 2, randomized, double-blind, double-dummy, positive drug parallel controlled, multicenter trial to evaluate efficacy and safety of within 8 weeks (including 8 weeks) treatment of Anaprazole 40mg QD, 60mg QD compared with…
- Conditions
- Reflux Esophagitis, Gastroesophageal Reflux, Esophagitis, Esophageal Motility Disorders
- Trial name
- NCT05604261
- Testing
- Anaprazole sodium 40 mg, Anaprazole sodium 60 mg, Rabeprazole sodium 20 mg
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
GERD
Epidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of GERD
To describe the frequency, type and severity of the symptoms in patients visiting the GI or internal physicians, with symptoms consistent with gastroesophageal reflux disease (GERD)
- Trial name
- NCT00524355
- Where
- 2 sites in Vietnam
- Volunteers
- 2,717 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
An Evaluation of the Medtronic Gatekeeper System in the Treatment of SUBJECTS With Gastroesophageal Reflux Disease (GERD)
The purpose of the study is to demonstrate the intended use of the Gatekeeper Reflux Repair System to provide symptomatic relief is subjects with gastroesophageal reflux disease.
- Trial name
- NCT00200044
- Testing
- Gatekeeper Reflux Repair System
- Where
- 11 sites in United States, Netherlands
- Volunteers
- 143 people
- Sponsor
- MedtronicNeuro
Gastroesophageal Reflux Disease
Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease
The purpose of this study is to evaluate the impact of gastroesophageal reflux disease (GERD) treatment in primary care setting on symptom control and daily life in symptomatic GERD patients, using both GERD questionnaire and…
- Trial name
- NCT01432392
- Where
- 2 sites in Bulgaria
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Esophagitis, Reflux, Esophagitis, Peptic
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
This is a study to assess the efficacy and safety of 8 weeks of treatment with Dexlansoprazole modified release (MR)(60 mg daily and 90 mg daily) compared to Lansoprazole (30 mg daily) in healing subjects with endoscopically…
- Trial name
- NCT00251719
- Testing
- Dexlansoprazole MR, Lansoprazole
- Where
- 144 sites in United States, Australia and 14 more
- Volunteers
- 2,054 people
- Sponsor
- Takeda
Erosive Esophagitis(EE), Gastroesophageal Reflux Disease (GERD)
TAK-438 - Safety, Blood Levels & Effects of Repeated Doses
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TAK-438 in healthy, non-Japanese men male subjects following a randomized, double blind, placebo controlled, sequential panel…
- Trial name
- TAK-438_107 (NCT02141711)
- Testing
- TAK-438
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Takeda
Heartburn, Gastroesophageal Reflux Disease
Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)
A double-blind study comparing Esomeprazole Magnesium 40 mg once daily and Lansoprazole 30 mg twice daily to control the symptoms in patients with gastroesophageal reflux disease (GERD) with continued heartburn symptoms with a…
- Trial name
- NCT00637845
- Testing
- Esomeprazole Magnesium, Lansoprazole
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
Chest Pain, Gastroesophageal Reflux
Chest Pain Pilot Study
The purpose of this study is to compare the efficacy of Nexium® with placebo in relief of acid related pain or discomfort in the chest.
- Trial name
- NCT00251901
- Testing
- Esomeprazole
- Where
- 80 sites in Canada, Denmark and 4 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca